Floatz logo

Prednisone

Skin Squamous Cell Carcinoma

Dana-Farber Cancer InstituteSmall moleculePhase 4 / ApprovedActive
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
81/ 100

Competitive context

55 Active assets in the Skin Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Sirolimus
Dana-Farber Cancer Institute
Phase 4BB
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Regeneron Pharmaceuticals
Phase 3BB
Technetium-99
Institut de Cancérologie de Lorraine
Phase 3BB
Everolimus
Dana-Farber Cancer Institute
Phase 4BB
Indocyanine Green
Institut de Cancérologie de Lorraine
Phase 3BB

View all 50 →

Same molecule, other indications

Prednisone is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedActive
BBB
Indicative · Phase 4
74 / 100
View asset →
diffuse large B-cell lymphomaActive
BBB
Indicative · Phase 4
74 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →